Immunocore (IMCR) had its "buy" rating reaffirmed by HC Wainwright. They now have a $100.00 price target on the stock.
KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma [Yahoo! Finance]
KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma
Enodia Therapeutics Appoints Dr. Yvonne McGrath as Chief Scientific Officer to Accelerate Upstream Targeted Protein Degradation Platform
Immunocore (IMCR) had its "buy" rating reaffirmed by HC Wainwright. They now have a $100.00 price target on the stock.